Clinical Trials · NCT03031535
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Dauntless Pharmaceuticals
- Enrollment
- 32
- Start date
- Jan 2017
- Locations
- 1 site, United States
- Primary endpoint
- Percentage of subjects reporting adverse events (AEs)/serious adverse events (SAEs).